Jonathan Isaacsohn
Director and Chairman of the Board
Dr. Jon Isaacsohn has served as Chief Executive Officer of CinRx Pharma since co-founding the company in 2015 and serves as a member of the company’s Board of Directors. Jon also served as founding Chief Executive Officer of a CinRx portfolio company, CinCor Pharma. He continues to serve as the Chief Executive Officer of CinRx’s other portfolio companies, including CinDome, CinSano, and CinFina. Prior to co-founding CinRx Pharma in 2015, Jon served as Chief Medical Officer for Teva Pharmaceuticals where he was responsible for developing Teva’s Specialty Drugs. and overseeing the New Therapeutic Entities (NTEs) initiative across all therapeutic areas. He was Executive Vice President, Head of Medical & Regulatory Affairs at Medpace, a global leader in research-based drug development for nearly 15 years. Jon was a co-founder of the Metabolic & Atherosclerosis Research Center in Cincinnati, OH. During his career, Jon has been involved in developing numerous drugs from early phases through global submissions in various therapeutic areas. He trained in Internal Medicine and Cardiology at Harvard Medical School and was a member of the cardiology faculty at Yale Medical School.
Paul Sekhri
President and Chief Executive Officer
Mr. Sekhri has over 30 years of experience in the Life Science Industry. His experience encompasses senior management in large corporate pharmaceutical and biotechnology companies, as well as private equity and venture capital. Mr. Sekhri is President and Chief Executive Officer of vTv Therapeutics, Inc. Most recently he served as President and CEO of eGenesis, Inc. from 2019-2022 where he remains a Board Member and Senior Advisor to the Chairman. Prior to joining eGenesis, he was President and CEO of Lycera Corp. from 2015-2019. Prior to this, he served as Senior Vice President, Integrated Care for Sanofi from 2014-2015. Previously, he served as Chief Strategy Officer and Group Executive Vice President, Global Business Development for Teva Pharmaceutical Industries, Ltd. Prior to joining Teva, he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004-2009, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. Previously, Mr. Sekhri spent five years at Novartis as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG.
Mr. Sekhri has been a director on more than 30 private, public company, and non-profit Boards and is currently a member of the Board of Directors of Axcella Therapeutics, eGenesis, Inc., Ipsen, S.A., Likeminds, Longboard Pharmaceuticals, Oryn Therapeutics, Spring Discovery and Veeva Systems Inc. Mr. Sekhri is also the Chairman of the Board of Compugen Ltd. and Chairman of Board of Supervisory Directors of Pharming N.V. Additionally, he is on the Board of Directors of The Metropolitan Opera, The English Concert in America and was a member of the Board of Trustees of Carnegie Hall. He is Chairman of the Board of the Knights Ensemble, and most recently was nominated as Chairman of the Board of Trustees of Young Concert Artists, Inc.
John Fry
Director
John Fry is the 14th president of Drexel University. Following his appointment at Drexel in 2010, John set out to transform the institution into a private research university with a strong public purpose – an institution that harnesses its strengths in cooperative education, translational research, online education and entrepreneurship to serve students, its neighborhood, the city and nation. Prior to Drexel, John was president of Franklin & Marshall College, executive vice president of the University of Pennsylvania, and a management consultant for the higher education and nonprofit sectors. John graduated from Lafayette College and earned a master’s degree in business administration from New York University Stern School of Business.
Chandresh Harjivan
Director
Dr.Chandresh Harjivan is the President, Chief Operating Officer and Co-Founder of SaponiQx, funded by AgenusBio and GingkoBioworks, and has over 15 years of experience in management consulting. Dr. Harjivan has dedicated his career to improving public health, first within the pharmaceutical and health care industries, and then in the public sector. His career has led him to work at such companies as PwC and Boston Consulting Group, where he led public health consulting. He has advised companies, NGOs, and governments on crucial issues, including understanding the epidemiology of existing and emerging diseases, the development and delivery of technologies against those diseases—whether new diagnostics, drugs, vaccines, or digital tools—as well as advising on where to make healthcare investments. Dr. Harjivan graduated from Massachusetts College of Pharmacy and Health Sciences in 1995 with a Bachelor of Science in Pharmacy and received a Master of Public Health from Johns Hopkins University, a Master of Business Administration from Oxford University, and a Doctor of Pharmacy from the University of Maryland.
Keith Harris
Director
Dr. Keith Harris is a London-based investment banker and financier with a 30-year career as a senior corporate finance and takeover advisor, having held senior executive positions at leading institutions including Morgan Grenfell, Drexel Burnham Lambert, Apax Partners, and HSBC Investment Bank. While serving in these roles, he advised on hundreds of debt and equity issues as well as complex cross border transactions. Keith left HSBC to pursue a number of interests as chairman or non-executive director of a range of public and private companies. He became Executive Chairman and an investor in Seymour Pierce (now part of Cantor Fitzgerald), organizing a buyout group that acquired the bank. He joined the board of MeiraGTx in 2015. Keith obtained his Doctorate in Economics in 1977 and embarked on a career in investment banking.
Hersh Kozlov
Director
Hersh Kozlov is the managing partner of the Cherry Hill, New Jersey office of Duane Morris, a law firm with more than 800 attorneys in the United States and internationally. With over thirty years of experience, Hersh provides counseling to clients in the areas of litigation, federal and state regulatory matters, gaming law and complex financial institution management. Hersh has managed numerous matters involving complex commercial litigation and has served as lead counsel before both federal and state courts in New Jersey and elsewhere. He was certified by the New Jersey Supreme Court as a civil and criminal trial attorney, having received his initial certification in 1984 and having been twice re-certified thereafter. He has represented investment banks and lenders, private equity firms, financial institutions and banks, and gaming companies in jurisdictions both domestic and international. In addition to his directorship at vTv, Hersh serves on the board of directors of The Bancorp, Inc. (TBBK NASDAQ). He has previously been a member of the board of directors of Resource America, Inc. (REXI NASDAQ), where he served as the lead independent director Jeff Banks, Inc. (JEFF NASDAQ) TRM Corporation (TRM NASDAQ) Hudson United Bank (HUB NYSE) US Healthcare Life Insurance Company and as a member of the Board of Directors of Princeton Insurance Company and the Healthcare Insurance Exchange. Hersh has also served as counsel to the board of directors of US Healthcare, Inc. Hersh graduated from Temple University with a B.A. degree in 1969 and graduated from Case Western Reserve University School of Law in 1972, which has identified and honored him as an outstanding graduate.
Fahed Al Marzooqi
Director
Dr. Fahed Al Marzooqi is the Chief Operating Officer of G42 Healthcare. In his current capacity, he leads the entire business operation. Dr. Fahed has over 15 years’ experience with large and diverse organizations. Prior to joining G42 Healthcare, he was the Chief Administrative Officer at Cleveland Clinic Abu Dhabi, where he was an integral part of multiple high-impact strategic programs for the hospital. Dr. Fahed led a multitude of business-critical assignments with varying degrees of complexity and has taken on progressive responsibilities to deliver strategic healthcare projects throughout his tenure. Dr. Fahed graduated with a Bachelor of Science in Mathematics and a Doctorate in Medicine from Dalhousie University in Canada. This was followed by a five-year residency program in anesthesiology at the University of British Columbia in Vancouver.
Rich Nelson
Executive Vice President, Corporate Development
In addition to his role as Executive Vice President Corporate Development for vTv Therapeutics, Rich Nelson is also Executive Vice President Corporate Development for Vericast, where Rich is responsible for the identification and execution of global merger and acquisition opportunities. In this role, Rich works with business leaders to source, negotiate and close acquisitions, joint ventures and partnerships that complement Vericast’s long-term vision and strategy. Rich brings more than 25 years of experience in mergers and acquisitions. Prior to Vericast, Rich served as Senior Vice President of Global Corporate Development at The Nielsen Company. Rich also served as Managing Director, Mergers and Acquisitions at IAC/InterActive Corp. Previously, Rich had been President and Co-Founder of Trendum, n/k/a Nielsen BuzzMetrics and SVP/General Counsel of RSL Communications, a telecommunications company. Rich began his career as a mergers and acquisition attorney at Skadden Arps. Rich earned his Bachelor of Business Administration in Finance with High Distinction from the Ross School of Business at the University of Michigan and a J.D. from New York University School of Law. Rich is a member of the National Advisory Board for the University of Michigan Rogel Cancer Center, the Board of Directors of Think Pink Rocks breast cancer charity, and a former member of the Board of Directors of Reply.com, RSL COM U.S.A. and Trendum, Inc. Rich is an active venture investor and advisor to various stage private companies and their Boards, including Woolsey Pharmaceuticals.
Howard Weiner
Director
Dr.Howard L. Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Brigham MS Center and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital in Boston which has over 250 scientists and investigates five major brain diseases: Multiple sclerosis, Alzheimer’s disease, ALS, Parkinson’s disease and brain tumors. He has pioneered immunotherapy in MS and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer’s Disease, ALS, stroke and brain tumors. He has also pioneered the investigation of the mucosal immune system for the treatment of autoimmune and other diseases and the use of anti-CD3 to induce regulatory T cells for the treatment of these diseases. He discovered Th3 regulatory T cells which act via TGF-β, now recognized as a central cytokine in immune system differentiation and he is currently at the forefront of investigating the microbiome in MS and modulating the microbiome by oral administration of microRNAs. Many of his discoveries in basic neuroimmunology are being translated to human disease including MS, ALS, and AD. He established the Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB) observational cohort of 2300 MS patients at the Brigham and Women’s Hospital now in its 20th year to deeply phenotype MS patients and the development of precision medicine for MS. In 2004, Harvard Medical School honored him with the establishment of the Howard L. Weiner Professorship of Neurologic Diseases. Howard is the 2007 recipient of the John Dystel Prize for MS Research and in 2012 he received the NIH Director’s Transformative Research Award for investigating the innate immune system in Alzheimer’s disease. Howard holds a B.A. from Dartmouth College and an M.D. from the University of Colorado School of Medicine.